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Abstract
Background: We compared the outcome of patients who received non-image-guided intensity-modulated
radiotherapy (IMRT) with those who received helical tomotherapy (HT), a daily image-guided radiotherapy (IGRT),
after surgery for oral cavity cancer (OCC).
Methods: During the period November 2006 to December 2013, a total of 152 postoperative OCC patients underwent
either IMRT (n = 79) or daily IGRT (n = 73) 4 to 6 weeks after surgery. Patients in the IMRT group received 6 MV photon
beams to 7 fields and those in the IGRT group received daily fractions of 1.8 or 2 Gy on five consecutive days.
Results: Patients who received daily IGRT had higher 5-year overall survival than those who received IMRT (87 % versus
48 %, p = 0.015). The local progression-free survival rate was also higher in patients who received IGRT (85 % versus
58 %, p = 0.006). More patients in the IGRT group completed the package of overall treatment time in≤ 13 weeks and
completed their course of radiation therapy in≤ 8 weeks than patients in the IMRT group (89 % versus 68 %, p = 0.002;
84 % versus 58 %, p = 0.001), respectively. The rate of local failure in the primary tumor area was 24.0 % in the IMRT
group and 6.8 % in the IGRT group. Among patients with primary local failure, the marginal failure rate was 52.6 % in
the IMRT group and 0 % in the IGRT group.
Conclusions: For patients with locally advanced OCC, postoperative IGRT results in better overall survival,
better local progression-free survival, less marginal failure and shorter overall treatment time than postoperative
non-image-guided IMRT.
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Background
Intensity-modulated radiation therapy (IMRT) is safe
and efficacious in the adjuvant setting for oral cavity
cancer (OCC) [1–4]. Compared with conventional radio-
therapy, IMRT provides better normal tissue protection
by producing highly conformal doses of radiation to
targets and sharp dose gradients between targets and
surrounding critical structures [5]. Nonetheless, patients
with head and neck cancer tend to experience changes
in soft tissue and body weight throughout the course of
radiation therapy, which have an impact on the delivered
dose [6]. Zeidan et al. [7] found that more than 10 % of
patients with head and neck cancer who underwent
imaging every other treatment day had setup errors of ≥
5 mm. Image-guided IMRT provides an excellent mech-
anism to account and correct for patient setup errors.
Den et al. [8] demonstrated that the use of image-guided
radiotherapy (IGRT) for position verification and align-
ment resulted in improvement in margin shrinkage due
to decreased radiation exposure to normal tissues.
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Helical tomotherapy (HT) is an IGRT system compris-
ing megavoltage computed tomography (MVCT) that
provides precise delivery of photons to a specific target
region, thereby sparing critical organs from exposure to
radiation and reducing the toxic effects associated with
radiation therapy [3, 9–11]. HT has also been demon-
strated to have better target volume dose conformity
and homogeneity than IMRT [12–14]. However, there is
a lack of consensus in the literature as to whether IGRT
results in better survival than non-IGRT.
In this study we compared the clinical outcome of
patients who received non-image-guided IMRT with




During the period December 2006 to December 2013,
189 patients with OCC underwent IMRT without image
guidance or daily HT at the Far Eastern Memorial
Hospital. Of those patients, 152 individuals without a
history of disease recurrence after surgery who received
radiotherapy with or without concurrent chemotherapy
were retrospectively enrolled. All patients were initially
evaluated by a multimodality treatment team consisting
of an otolaryngologist, oral surgeon, medical oncologist,
and radiation oncologist. Staging investigations included
a complete medical history and physical examination,
fiber-optic endoscopic evaluation, complete blood cell
counts, liver function tests, chest X-ray, preoperative
magnetic resonance imaging (MRI) of the head and neck
region, and a dental evaluation. Bone scans and com-
puted tomography (CT) of the chest and abdomen were
obtained whenever possible before the beginning of
treatment. All tumor specimens were staged according
to the tumor-node-metastasis (TNM) staging system
(AJCC cancer staging manual, 6th edition).
Radiation therapy
Radiation therapy with or without concurrent chemora-
diation therapy (CCRT) was initiated 4 to 6 weeks after
surgery using 6 MV photon beams and a 7-field IMRT
plan or daily HT with a simultaneous-integrated boost or
sequential techniques comprising 1.8 or 2 Gy fractions on
five consecutive days. The choice of dose was made at the
discretion of the primary oncologist and the choice of
treatment modality was left up to the patients. In Taiwan,
only non-IGRT is covered by the National Health
Insurance system. Therefore, patients who chose to
undergo HT had to pay out-of-pocket for the procedure.
Target regions and normal structures were contoured
using the Pinnacle 3 Treatment Planning System (Philips
Healthcare, Madison, Wisconsin, USA). The preoperative
MR images were retrieved on a Pinnacle workstation and
fused with the CT images by rigid image registration in all
patients to contour the postoperative flap and confirm the
location of the preoperative gross tumor to overcome the
possibility of miss-contouring of the gross tumor due to
structural changes caused by surgery.
Delineation of target volumes
The clinical target volumes (CTVs) were determined
according to the incidence and location of metastatic
neck nodes from various head and neck subsites as
previously reported [3, 15]. Briefly, CTV1 was defined as
the area encompassing the preoperative gross tumor and
postoperative flap plus a 0.8- to 1-cm margin, which
included the resection bed with soft-tissue invasion by
the tumor or extracapsular extension (ECE) by meta-
static neck nodes truncating air, and uninvolved bones.
CTV2 was defined as a high-risk subclinical area primarily
including the pathologically uninvolved cervical lymph
nodes, deemed as elective nodal regions, or prophylactic-
ally treated neck areas. CTV3 was designated as a low-risk
area of potential subclinical disease. To account for organ
motion and patient setup errors, the CTVs were used to
construct the planning target volumes (PTVs). PTV1 and
PTV2 included CTV1 and CTV2 plus a margin of 3 mm
for HT and 5 mm for IMRT, while PTV3 included CTV3
plus a margin of 5 mm for HT and 7 mm for IMRT.
PTV1 consisted of 60–66 Gy in 30–33 fractions; high-risk
OCC patients received 64–66 Gy and intermediate-
risk OCC patients received 60 Gy. PTV2 comprised
59.4–60 Gy in 30–33 fractions and PTV3 consisted of
46–54 Gy in 23–33 fractions.
Additionally, no more than 20 % of the PTV received
more than 110 % of its prescribed doses, and no more
than 1 % of any PTV received less than 93 % of its pre-
scribed doses. The dose constraints for organs at risk
(OARs) were as follows: (1) a maximum dose of 54 Gy
for brainstem; (2) a maximum dose of 45 Gy for spinal
cord; (3) a maximum dose of 45 Gy for optic chiasm
and optic nerve; (4) a mean dose of < 30 Gy for bilateral
parotid glands with a median dose of < 26 Gy. For
parotid glands with a volume larger than 20 mL, the me-
dian dose was < 20 Gy; (5) a mean dose of 2/3 of glottic
larynx < 50 Gy (6) a mean dose of < 50 Gy for inner ear;
and (7) a maximum dose of 70 Gy for mandible.
Patients treated by HT underwent daily IGRT via
MVCT. The daily MVCT images were fused with the
original treatment planning prior to administration of
each fraction based on soft tissue and bony structures.
After automatic registration, the position was corrected
manually in order to align the PTV.
Chemotherapy
Studies have shown that close or positive resection margin,
extracapsular spread, perineural invasion, lymphovascular
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space involvement, primary tumor stage T3-4 and two or
more positive lymph nodes are significant predictors of
poor overall survival and local control in patients with
head and neck cancer [16–18]. Patients with any of those
prognostic factors underwent concurrent chemotherapy.
Concurrent chemotherapy comprising weekly intravenous
administration of cisplatin (30 mg/m2) plus fluoroura-
cil (5-FU, 425 mg/m2) and leucovorin (30 mg/m2)
was received by 85 % (n = 67) of patients in the IMRT
group and 89 % (n = 65) of patients in the HT group
(Table 1).
Definition of relapse and delineation of locoregional failure
When available, image studies delineating the site of
locoregional failure were fused with the treatment plan-
ning CT scan. Otherwise, anatomic landmarks were used
to determine the failure site. Failure was defined as
infield if >95 % of the volume of the recurrent tumor fell
within the CTV, marginal if 20–95 % of the volume was
within the CTV, and out of field if 20 % fell within the
CTV [19].
Follow-up
All patients were evaluated at least once a week during
radiotherapy. Upon completion of radiation, patients
were evaluated every 3 months for the first 2 years. At
each follow-up visit, a fiber-optic endoscopic examin-
ation and palpation of the neck were performed as part
of the physical examination. Post-treatment MRI of the oral
cavity and neck was done 1, 3, and 6 months after comple-
tion of radiotherapy. Acute toxicities (occurring < 90 days
after initiation of radiotherapy) and late toxicities (occur-
ring > 90 days after initiation of radiotherapy) were defined
and graded according to the Common Terminology
Criteria for Adverse Events v3.0 (CTCAE v3.0). The
earliest date of detecting grade 3 or worse toxicity
was recorded.
Statistical methods
Descriptive statistics (mean, median, proportions) were cal-
culated to characterize the patients, diseases, treatment fea-
tures and toxicities after treatment. The overall survival
(OS), disease-free survival (DFS), locoregional progression-
free survival (LRPFS), local progression-free survival
(LPFS), regional progression-free survival (RPFS) and
metastasis-free survival (MFS) rates were estimated using
the Kaplan-Meier product-limit method and log-rank tests
[20]. Significant variables in the univariate analyses were
included in a multivariate regression model to identify the
most important factors associated with outcome. Cox
proportional-hazards analysis was used to determine the
relative contribution of various factors to outcome. Free-
dom from local and regional progression was defined as
the absence of a primary tumor and regional lymph nodes
on physical examination and on any radiographic examin-
ation (CT and MRI). Durations were calculated from the
date of pathologic proof. All analyses were performed using
the statistical package SPSS for Windows (Version 20.0,
IBM Corporation, Armonk, NY, USA).
All procedures performed in studies involving human
participants were in accordance with the ethical standards
of the institutional and/or national research committee
and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards. The need
for informed consent was waived by the Institutional
Review Board of the Far Eastern Memorial Hospital
(FEMH-IRB- 104008-E) and retrospective data were
collected after receiving approval from the Institutional




One hundred and forty-eight men and four women were
included in the study. The median age was 52 years
(range, 24–78 years). As seen in Table 1, the dominant
subsites of oral cancer in the IMRT and HT groups were
oral tongue (32 % and 48 %) and buccal mucosa (43 %
and 34 %). There were no significant differences in oral
cancer location between the two groups of patients.
There were also no significant differences between the
IMRT and HT groups in resection margin status, extra-
capsular spread, pathological stage, receipt of concurrent
chemotherapy, or RT dose. However, the percentage of
patients with lymphovascular space involvement (LVSI)
was significantly higher among HT-treated patients than
among those who received non-image-guided IMRT
(63 % versus 39 %, p = 0.003). Also, the percentage of
patients with perineural involvement (PNI) was signifi-
cantly higher in the HT group than in the IMRT group
(82 % versus 62 %, p = 0.006). (Table 1) The median dose
of radiation in both groups was 66 Gy. In this study, the
total time from surgery to completion of therapy (pack-
age of overall treatment time, POTT) was dichotomized
into >13 weeks and ≤ 13 weeks and the overall duration
of radiation therapy (overall treatment time of radiation
therapy (OTTRT)) was dichotomized into > 8 weeks
and ≤ 8 weeks. We found that significantly more patients
in the HT group completed the package of overall treat-
ment time in ≤ 13 weeks and completed their course of
radiation therapy in ≤ 8 weeks than patients in the IMRT
group (POTT, 84 % vs 58 % (p = 0.001); OTTRT, 89 % vs
68 %, (p = 0.002)).
Treatment outcomes
The median follow-up was 60 months (range, 4 to
80 months). The actuarial 5-year overall survival (OS),
disease-free survival (DFS), locoregional progression-free
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survival (LRPFS), local progression-free survival (LPFS),
regional progression-free survival (RPFS) and metastasis-
free survival (MFS) rates in each group are listed in
Table 2. There were no significant differences in the
majority of those outcome measures; however, the rates of
overall survival and local progression-free survival were
significantly higher in the HT group than in the non-
image-guided IMRT group (Table 2 and Fig. 1a-b).
Also, Kaplan–Meier estimates of 5-year OS and 5-
year LPFS in patients with prognostic factors such as
positive resection margin, positive extracapsular
spread, positive perineural invasion, positive lympho-
vascular space involvement, two or more positive
lymph nodes, or tumor stage T3/T4, revealed that
patients who received HT had better overall survival
(Fig. 2a to f ) and local progression-free survival
(Fig. 3a to e) than patients who received IMRT
without image guidance. Significant variables in the
univariate analyses (ECE, PNI, LVSI, two or more
positive lymph nodes and T3,4) were included in a
multivariate regression model to identify the most
important factors associated with outcome. Cox
proportional-hazards analysis was used to determine
the relative contribution of various factors to out-
come. The results revealed that patients who under-
went IGRT had significantly better 5-year overall
survival rates (adjusted hazard ratio (HR) = 0.318;
95 % CI = 0.152-0.666, p = 0.002) and significantly better
5-year local progression-free survival than patients who
underwent IMRT without image guidance (HR = 0.211;
95 % CI = 0.076–0.591, p = 0.003) (Table 3).






Variable No. of patients (%)
Age (years)
Median 48 52 0.398
Range 29–78 24–78
Gender
Male 78 (98.7 %) 70 (95.9 %) 0.274
Female 1 (1.3 %) 3 (4.1 %)
Subsite
Oral tongue 25 (31.6 %) 35 (47.9 %) 0.348
Buccal mucosa 34 (43.0 %) 25 (34.2 %)
Alveolar ridge 8 (10.1 %) 7 (9.6 %)
Retromolar trigone 5 (6.3 %) 3 (4.1 %)
Floor of the mouth 2 (2.5 %) 2 (2.7 %)
Hard palate 2 (2.5 %) 1 (1.4 %)
Lip 3 (3.8 %) 0
Resection-margin status
Close or positive 39 (49.4 %) 42 (57.5 %) 0.313
Negative 40 (50.6 %) 31 (42.5 %)
Extracapsular spread
Positive 13 (16.5 %) 19 (26.0 %) 0.148
Negative 66 (83.5 %) 54 (74.0 %)
Perineural involvement
Positive 49 (62.0 %) 60 (82.2 %) 0.006
Negative 30 (38.0 %) 13 (17.8 %)
Lymphovascular space
involvement
Positive 31 (39.2 %) 46 (63.0 %) 0.003
Negative 48 (60.8 %) 27 (37.0 %)
Pathology stage:
Tumor stage
Stage I 6 (7.6 %) 8 (11.0 %) 0.532
Stage II 12 (15.2 %) 12 (16.4 %)
Stage III 18 (22.8 %) 15 (20.5 %)
Stage IVA 43 (54.4 %) 38 (52.1 %)
Primary tumor stage
T1 14 (17.7 %) 13 (17.8 %) 0.768
T2 22 (27.8 %) 25 (34.2 %)
T3 18 (22.8 %) 11 (15.1 %)
T4a 25 (31.6 %) 24 (32.9 %)
Regional lymph node stage
N0 39 (49.4 %) 38 (52.1 %) 0.302
N1 15 (19.0 %) 7 (9.6 %)
N2a 8 (10.1 %) 6 (8.2 %)
N2b 14 (17.7 %) 20 (27.4 %)
Table 1 Patient characteristics (Continued)
N2c 3 (3.8 %) 1 (1.4 %)
N3 0 1 (1.4 %)
Adjuvant concurrent
chemotherapy
Yes 67 (84.8 %) 65 (89.0 %) 0.442
No 12 (15.2 %) 8 (11.0 %)
RT dose






≤13 weeks 46 (58.2 %) 61 (83.6 %) 0.001
>13 weeks 33 (41.8 %) 12 (16.4 %)
OTTRT
≤8 weeks 54 (68.4 %) 65 (89.0 %) 0.002
>8 weeks 25 (31.6 %) 8 (11.0 %)
Abbreviations: ECOG Performance Status Eastern Cooperative Oncology Group
Performance Status, HT helical tomotherapy, IGRT image-guided radiotherapy,
IMRT intensity-modulated radiotherapy, non-IGRT non-image-guided
radiotherapy, OTTRT overall treatment time of radiotherapy, POTT
package of overall treatment time
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The local failure in the primary tumor area for both groups
The rate of local failure in the primary tumor area was
24.0 % (19/79) in the non-image-guided IMRT group
and 6.8 % (5/73) in the HT group. Of the 19 patients in
the IMRT group with local failure, 14 had perineural
invasion only, 10 had lymphovascular space involvement
only and 8 patients had concomitant perineural invasion
and lymphovascular space involvement. In addition, of
the 19 patients with local failure, 31.6 % (n = 6), had
infield failure, 52.6 % (n = 10) had marginal failure and
15.5 % (n = 3) had out-of-field failure. Of the 5 patients
with local failure after receiving HT, four had concomi-
tant perineural invasion and lymphovascular space
involvement. Failure was defined as infield in four of the
five patients and out-of-field in one of the five patients.
The influences of POTT and OTTRT on survival
In the non-IGRT group, the overall treatment time of
radiotherapy (OTTRT) was 6.5 weeks in 18 (22.8 %)
patients, 7 weeks in 33 (41.8 %) patients and 8 weeks in
53 (67.0 %) patients. In the IGRT group, the OTTRT
was 6.5 weeks in 23 (31.5 %) patients, 7 weeks in 46
(63.0 %) patients and 8 weeks in 65 (89.0 %) patients.
The total number of patients who received radiotherapy
for ≥7 weeks was 46 (58.2 %) in the IMRT group and 27
(40 %) in the IGRT group. The total number of patients
who received radiotherapy for ≥8 weeks was 25 (32 %)
in the non-IGRT group and 8 (11 %) in the IGRT group.
Kaplan–Meier survival estimates revealed that a
POTT ≤ 13 weeks was significantly associated with
better overall survival in both groups (p = 0.032 by the
log-rank test, 95 % CI, 0.24 to 0.96) (Fig. 4a). Comparison
of actuarial survival rates between both groups of patients
who completed the POTT in ≤ 13 weeks revealed that
patients in the IGRT group had significantly better overall
survival and better local progression-free survival than pa-
tients in the non-IGRT group (85.0 % vs 58.3 % (95 % CI,
0.24 to 0.96, p = 0.05) and 85.8 % vs 59.1 % (95 % CI, 0.31
to 0.97, p = 0.015), respectively).
Kaplan–Meier survival estimates revealed that an
OTTRT ≤ 8 weeks was significantly associated with
better local progression-free survival than an OTTRT >
8 weeks in both groups (72.3 % vs. 40.1 %, 95 % CI, 0.15
to 1.12, p = 0.021) (Fig. 4b). Comparison of actuarial
survival rates between both groups of patients with an
overall duration of therapy ≤ 8 weeks revealed that
patients in the IGRT group had significantly better over-
all survival and better local progression-free survival
than patients in the non-IGRT group (85.0 % vs 58.3 %
Table 2 The actuarial 5-year overall survival, disease-free survival,
locoregional progression-free survival, local progression-free
survival, regional progression-free survival and metastasis-free
survival rates in the intensity-modulated radiotherapy-treated
and helical tomotherapy-treated groups
Survival rate IMRT (non-IGRT) HT (IGRT) 95 % CI p value
5-year OS 47.5 % 86.7 % 0.53 to 0.64 0.015
5-year DFS 39.3 % 73.8 % 0.40 to 0.74 0.146
5-year LRPFS 49.8 % 69.8 % 0.37 to 0.77 0.104
5-year LPFS 58.4 % 85.2 % 0.58 to 0.70 0.006
5-year RPFS 81.2 % 81.4 % 0.62 to 0.72 0.653
5-year MFS 82.6 % 80.1 % 0.62 to 0.72 0.892
Abbreviations: DFS disease-free survival, HT helical tomotherapy, IGRT image-guided
radiotherapy, IMRT intensity-modulated radiotherapy, MFS metastasis-free survival,
non-IGRT non-image-guided radiotherapy, LRPFS locoregional progression-free
survival, LPFS local progression-free survival, OS overall survival, RPFS regional
progression-free survival
Fig. 1 The actuarial 5-year Kaplan–Meier survival estimates. a Overall survival curve; b Local progression-free survival curve for postoperative oral cavity
cancer patients treated with intensity-modulated radiation therapy (IMRT) or helical tomotherapy (HT), with or without concurrent chemotherapy
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Fig. 2 The actuarial 5-year Kaplan–Meier curves for overall survival curve according to risk factors in patients with postoperative oral cavity cancer
patients treated with intensity-modulated radiation therapy (IMRT) or helical tomotherapy (HT), with or without concurrent chemotherapy. a positive
resection-margin; b positive extracapsular spread (ECE); c positive perineural invasion (PNI); d positive lymphovascular space involvement (LVSI); e two
or more positive lymph nodes; f T3,4
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Fig. 3 The actuarial 5-year Kaplan–Meier estimates of local progression-free survival according to risk factors in postoperative oral cavity cancer
patients treated with intensity-modulated radiation therapy (IMRT) or helical tomotherapy (HT), with or without concurrent chemotherapy. a positive
resection-margin; b positive perineural invasion (PNI); c positive lymphovascular space involvement (LVSI); d two or more positive lymph nodes; e T3,4
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(95 % CI, 0.24 to 0.96, p = 0.05) and 88.0 % vs 56.2 %
(95 % CI, 0.15 to 1.12, p = 0.025), respectively).
Toxicities
Data on incurred toxicities in both groups of patients
with or without chemotherapy are detailed in Table 4.
No grade 3 xerostomia was noted in either group. The
incidence of grade 2/3 body weight loss was significantly
lower in the IGRT group than in the non-IGRT group
(p = 0.004). There were no significant differences in
incidence of grade 3 dermatitis (p = 0.180) or grade 2/3
dysphagea (p = 0.412) between the two groups. The con-
straints for critical organs in patients who underwent
IGRT or non-IGRT were the same. As the plan could be
accepted, the doses for the critical organs were within
limitation for both techniques that might cause the similar
adverse effects as non-IGRT. There were no differences in
incidence of fistula formation or mucositis between the
two groups. One reason for this finding might be because
the mucosa is part of the CTV in patients with OCC and
mucosal reactions dominate acute reactions regardless of
treatment modality. The incidence rates of leucopenia
(p = 0.007) and thrombocytopenia (p = 0.003) were
significantly higher in patients who underwent IMRT
without image guidance than in patients who under-
went IGRT (Table 4).
Table 3 The 5-year overall survival rate and local-progression free survival rate of postoperative oral cavity cancer patients under
prognostic factors treated with helical tomotherapy (HT, image-guided radiotherapy, IGRT) and intensity-modulated radiotherapy
(IMRT, non- image-guided radiotherapy, non-IGRT)
5-year OS 5-year LPFS
Prognostic factors Modality 95 % CI p value Modality 95 % CI p value
HT IMRT HT IMRT
Resection-margin 84.0 % 57.7 % 0.52 to 0.68, 0.008 92.5 % 28.6 % 0.51 to 0.77 0.006
ECE 76.6 % 31.7 % 0.39 to 0.65, 0.007 54.0 % 64.1 % 0.39 to 0.65 0.942
PNI 79.3 % 35.2 % 0.15 to 0.97 0.005 82.3 % 43.9 % 0.28 to 0.85 0.003
LVSI 77.0 % 50.0 % 0.49 to 0.64 0.012 78.8 % 0.0 % 0.54 to 0.74 0.001
Two or more positive lymph nodes 74.0 % 40.3 % 0.41 to 0.61 0.010 77.0 % 26.2 % 0.29 to 0.85 0.003
T3,4 72.8 % 38.7 % 0.39 to 0.73 0.017 79.5 % 39.8 % 0.25 to 1.02 0.005
Hazard ratio (HR)a 95 % CI P value Hazard ratio (HR)a 95 % CI P value
Modality HT vs IMRT 0.32 0.15 to 0.67 0.002 0.21 0.08 to 0.59 0.003
Abbreviations: CI, confidence interval; ECE extracapsular spread, HT helical tomotherapy, IMRT intensity-modulated radiotherapy, LPFS local progression-free survival
rate, LVSI lymphovascular space involvement, OS overall survival rate, PNI perineural invasion
aHazard ratios were derived from Cox proportional hazards regression after adjusting ECE, PNI, LVSI, two or more positive lymph nodes and T3,4 variables
Fig. 4 a The actuarial 5-year Kaplan–Meier curves for overall survival in postoperative oral cavity cancer patients treated with radiotherapy with a
package of overall treatment time (POTT) less than 13 weeks or more than 13 weeks; b The actuarial 5-year -year Kaplan–Meier estimates of local
progression-free survival in postoperative oral cavity cancer patients treated with radiotherapy with an overall treatment time of radiation therapy
(OTTRT) less than 8 weeks or longer than 8 weeks
Hsieh et al. BMC Cancer  (2016) 16:139 Page 8 of 13
Cox proportional-hazards regression revealed that
overall survival was significantly associated with modal-
ities (IGRT versus non-IGRT: HR = 0.46; 95 % CI =
0.22–0.79, p = 0.042) and anemia (increasing grade of
anemia, HR =2.57; 95 % CI = 1.16–5.67, p = 0.020) and that
LPFS was significantly associated with modalities
(IGRT versus non-IGRT: HR = 0.18; 95 % CI = 0.06–
0.56, p = 0.003) and anemia (HR = 5.83; 95 % CI =
2.22–15.31, p < 0.001) (Table 5).
Discussion
The long-term overall survival rate among patients with
head and neck carcinoma cancer who were treated with
standard fractionation combined with concurrent cisplatin
was 48 % in the Radiation Therapy Oncology Group
(RTOG) 0129 trial [21] and 46 % in the RTOG 9501 trial
[16]. Similarly, the 5-year overall survival rate in the non-
IGRT group in this study was 47.5 % (Table 2). After
adjusting for ECE, PNI, LVSI, two or more positive lymph
nodes and T3,4 in the Cox proportional-hazards regres-
sion model, we found that patients who underwent IGRT
had significantly better OS and LPFS than patients who
received IMRT without image guidance (Figs. 2 and 3,
Table 3). One possible reason for the striking improve-
ment in overall survival and local disease control out-
comes might be attributed to the better target volume
Table 4 Acute toxicities in high-risk oral cavity cancer patients
treated with postoperative helical tomotherapy (HT, image-guided
radiotherapy, IGRT) and intensity-modulated radiotherapy (IMRT,
non- image-guided radiotherapy, non-IGRT) with or without






No. of patients (%)
aXerostomia (Acute)
Gr.1 54 (68.4 %) 54 (74.0 %) 0.445





Gr.1 7 (8.9 %) 4 (5.5 %) 0.627
Gr.2 49 (62.0 %) 44 (60.3 %)




Gr.1 33 (41.8 %) 33 (45.2 %) 0.180
Gr.2 30 (47.6 %) 33 (45.2 %)




Gr.1 51 (64.6 %) 62 (84.9 %) 0.004
Gr.2 27 (34.2 %) 11 (15.1 %)




Gr.1 53 (67.1 %) 55 (75.3 %) 0.472
Gr.2 11 (13.9 %) 9 (12.3 %)






Yes 1 (1.3 %) 3 (4.1 %) 0.351
No 78 (98.7 %) 70 (95.9 %)
Anemia
Normal 11 (13.9 %) 15 (20.5 %) 0.507
Gr.1 58 (73.4 %) 51 (69.9 %)
Gr.2 10(12.7 %) 7 (9.6 %)
Table 4 Acute toxicities in high-risk oral cavity cancer patients
treated with postoperative helical tomotherapy (HT, image-guided
radiotherapy, IGRT) and intensity-modulated radiotherapy (IMRT,
non- image-guided radiotherapy, non-IGRT) with or without





Normal 14 (17.7 %) 24 (32.9 %) 0.007
Gr.1 49 (62.0 %) 25 (34.2 %)
Gr.2 9 (11.4 %) 17 (23.3 %)
Gr.3 5 (6.3 %) 6 (8.2 %)
Gr.4 2 (2.5 %) 1 (1.4 %)
Gr.5 0 0
Thrombocytopenia
Normal 15 (19.0 %) 31 (42.5 %) 0.003
Gr.1 59 (74.7 %) 41 (56.2 %)
Gr.2 3 (3.8 %) 1 (1.4 %)
Gr.3 2 (2.5 %) 0
Gr.4 0 0
Gr.5 0 0
aAcute xelostomia: Acute toxicity is defined as occurring < 90 days after beginning RT
bToxicity grade was determined according to the Common Terminology Criteria
for Adverse Events v3.0 (CTCAE v3.0)
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dose conformity, homogeneity of daily image-guided HT
compared to non-image-guided IMRT [12–14, 22]. More
importantly, IGRT allows for daily adjustment in setup
error. In fact, this is pointed to by the large number of
marginal failures in the non-IGRT group.
Studies have shown that POTT and OTTRT are asso-
ciated with overall survival and locoregional control. For
example, Ang et al. [23] reported that the 5-year overall
survival rates and locoregional control rates in patients
with advanced head and neck cancer were respectively
about 76 % and 38 % lower in patients who completed the
package of overall treatment time in > 13 weeks than in
those who completed it in < 11 weeks. Similarly, Langendijk
et al. [24] reported that high-risk and intermediate-risk
OCC patients with a POTT >13 weeks had a worse
3-year locoregional control rate (71 %) than patients
with a POTT ≤ 11 weeks (86 %). In addition, Rosenthal et
al. [25] found that patients with a POTT <100 days had
significantly better overall survival than those who com-
pleted the POTT in more than 100 days. Similarly, we also
noted that a POTT ≤13 weeks was associated with better
5-year overall survival than a POTT > 13 weeks (Fig. 4a).
Additionally, different modalities were found to contribute
to the duration of POTT. The number of patients who
completed the POTT in < 13 weeks was significantly
higher in the IGRT group than in the non-image-guided
IMRT group (p = 0.001). That finding might explain, at
least in part, why the 5-year OS and LPFS rates were
higher in the IGRT group than in the non-IGRT group.
In a large review of retrospective data on patients with
head and neck cancer who underwent RT, Fowler et al.
[26] found that the average rate of loss of locoregional
control per week of prolongation of OTTRT was 9 %.
Ang and coworkers [23] randomized 151 patients with
advanced head and neck cancer to receive either 63 Gy
over a 7–week period or 63 Gy over a 5–week period
and found that the locoregional control rate was 15 %
higher in patients treated for 5 weeks than in those who
received therapy for 7 weeks. Langendijk et al. [24]
reported that OTTRT >8 weeks resulted in worse 3-year
overall survival and locoregional control than OTTRT ≤
8 weeks in high- and intermediate-risk OCC patients.
Moreover, Muriel et al. [27] found that the 5-year
locoregional control rate was 75 % in patients with a
postoperative irradiation time ≤ 55 days and 68 % in
those who received radiation for more than 56 days.
In our previous study we showed that around 80 %
of patients treated with IGRT could complete the
OTTRT within 8 weeks [3]. In this study, we found
that patients treated with IGRT were more likely to
complete OTTRT within 6.5, 7 or 8 weeks than patients
who received non-IGRT. In the current study, patients
who completed the OTTRT in ≤ 8 weeks had better 5-
year LPFS than those who completed the OTTRT in >
8 weeks (72.3 % vs. 40.1 %, p = 0.021, Fig. 4b).
Feng and coauthors reported that IMRT results in better
swallowing function and a reduced incidence of dysphagia
by reducing the dose of RT to pharyngeal constrictors and
other swallowing structures [28]. Den et al. [8] also found
that IGRT reduces the incidence of dysphagia in patients
with head and neck cancer by minimizing the exposure of
normal tissues to radiation. Additionally, PTV volumes
are important predictors of nutritional compromise and
have been used to predict weight loss during radiotherapy
in patients with head and neck cancer [29]. Also Capuano
et al. [30] found that a reduction in body weight of more
than 20 % was significantly correlated with treatment
interruption. Furthermore, Arrieta et al. [31] found that
the incidence of chemotherapy-induced hematologic tox-
icity was significantly higher among malnourished patients
Table 5 Results of Cox proportional hazards analysis after adjusting for modalities, xerostomia, mucositis, dermatitis, body weight loss,
dysphagia, fistula formation, anemia, leucopenia and thrombocytopenia
5-year OS 5-year LPFS
Adjusted factors Hazard ratio (HR) 95 % CI p value Hazard ratio (HR) 95 % CI p value
IGRT vs Non-IGRT 0.46 0.22–0.97 0.042 0.18 0.06–0.56 0.003
aXerostomia (Acute) 0.92 0.45–1.88 0.813 1.32 0.53–3.33 0.554
Mucositis 0.73 0.42–1.27 0.270 0.93 0.41–2.11 0.856
Dermatitis 1.05 0.68–1.63 0.821 0.60 0.32–1.11 0.103
Body weight loss 1.31 0.68–2.54 0.427 0.32 0.09–1.13 0.076
Dysphagia 0.93 0.60–1.45 0.762 0.56 0.27–1.19 0.122
Fistula formation or superficial cases of skin dehiscence 0.00 0.00–0.00 0.978 0.00 0.00–0.00 0.985
Anemia 2.57 1.16–5.67 0.020 5.83 2.22–15.31 0.000
Leucopenia 1.08 0.67–1.73 0.766 0.85 0.47–1.54 0.588
Thrombocytopenia 0.62 0.29–1.33 0.220 0.59 0.23–1.38 0.206
Abbreviations: CI confidence Interval, IGRT image-guided radiotherapy, LPFS local progression-free survival rate, OS overall survival rate
aAcute xelostomia: Acute toxicity is defined as occurring < 90 days after beginning RT
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than among well-nourished patients. With daily MVCT
monitoring, the margin of PTV in the IGRT group was
smaller than in the non-IGRT group; therefore, the
smaller volume in PTV after 3-dimention expansion in
the IGRT group could be expected. Markedly more pa-
tients in the non-IG-IMRT group than in the IGRT group
were unable to complete OTTRT within 7 or 8 weeks.
This might explain, at least in part, why a larger PTV mar-
gin in the non-image-guided plan influenced the OTTRT.
Clinically, there was markedly less grade 2/3 body weight
loss in the IGRT group than in the non-IGRT. In addition,
the rates of leucopenia and thrombocytopenia were mark-
edly lower in the IGRT group than in the non-IGRT group.
After adjusting for adverse factors, we found that IGRT
was associated with significantly better OS and LPFS than
non-IG-IMRT. (Table 5) Therefore, patients treated with
IGRT might have a better chance of completing OTTRT
within 8 weeks and hence a better overall outcome.
In our study, the rate of local failure was 24.0 % in the
non-IGRT group and 6.8 % in the IGRT group. Among
the patients with local failure, the marginal failure rate
was 52.6 % in the non-IGRT group and 0 % in the IGRT
group. The margin recipe for non-IGRT treatments
assumes a statistical 5 % D95 miss in 10 % of the pa-
tients [32]. Daily setup variations can range from 3 to
21 %, which will result in unrecognized geographic miss
and resultant target underdose [33]. Zeidan et al. [7]
found that more than 10 % of patients with head and neck
cancer had setup errors of ≥ 5 mm. Moreover, it has been
shown that soft tissue shrinkage causes a higher deviation
in delivered dose to the PTV and normal tissue outside
the PTV [34]. The above-mentioned results suggest that
daily image correction minimizes geographic misses and
decreases the probability of margin failure. The ranges in
variation of registration by daily MVCT for patients
treated by IGRT were analyzed retrospectively. The
variation in x-axis ranged from 6.4 to−8.7 mm and the
variation in the y-axis ranged from 4.7 to −9.7 mm. How-
ever, in our institute, the margin for CTV to expand to
PTV is 5 mm in non-IGRT system. This may be one of
the reasons for the higher marginal failure rate observed
in patients treated with non-IGRT. In addition, the rate of
weight loss in the non-IGRT group was higher than that
in the HT group, which may have led to more deviations
in the administered dose distribution with respect to the
planned dose, thereby resulting in worse dose coverage
and, hence, poorer local control and overall survival.
Putting these observations together, it is apparent that a
larger margin for CTV to expand to PTV should be
considered for non-IGRT.
Studies have shown that patients with head and neck
cancer who have inadequate insurance coverage and
those with low socioeconomic status have lower rates of
survival [35]. In addition, Allareddy et al. [36] found that
comorbid conditions and inadequate insurance coverage
were predictors of in-hospital mortality. In Taiwan, HT
is not covered by the universal National Health Insur-
ance program. Patients who elect to undergo the pro-
cedure must either pay out-of-pocket or have a robust
private health insurance policy to cover the expenses for
the procedure. Therefore, it is assumed that patients
who elected to undergo postoperative HT had the
economic means to do so.
In vitro studies of conventional photon radiation ther-
apy under normoxic conditions have demonstrated up
to three times the efficacy relative to anoxic conditions
[37]. Anemia was reported to be an independent prog-
nostic factor in squamous cell carcinoma of the head and
neck [38] and a predictive factor for local recurrence in
postoperative radiotherapy for head and neck cancer [39].
In this study, we also found that anemia was an independ-
ent predictor of poor OS and LPFS (Table 5).
This study has several limitations, most of which are re-
lated to its retrospective nature. The patients in our study
were treated by a consistent group of radiation, surgical,
and medical oncologists; however, these patients were not
selected or treated based on a prospective protocol, such
as fractionation regimen or simultaneous-integrated or se-
quential boost techniques, leading to heterogeneity in the
management of patients. However, all patients were
reviewed by the multidisciplinary tumor board, and hence,
all individuals were treated with a consistent treatment
philosophy. Second, the choice of treatment modality was
left up to the patients. In Taiwan, only IMRT is covered by
the National Health Insurance system. Therefore, patients
who chose to undergo HT had to pay out-of-pocket for
the procedure, which may indicate potential bias. Add-
itionally, the quality of both non-IGRT and IGRT planning
improved over time, which is partly evidenced by the
elimination of strictures in our later experience. Finally,
toxicity data were not prospectively collected but rather
abstracted from the medical records. Such a process is
limited by the underlying inadequacies of medical docu-
mentation when used for research purposes.
Conclusion
IGRT results in better overall survival and local
progression-free survival than IMRT without image guid-
ance in patients with locally advanced OCC. Our results
also indicate that patients whose overall duration of IGRT
is less than 8 weeks and whose total time from surgery to
completion of IGRT is ≤ 13 weeks have better local
progression-free survival and overall survival, respectively.
Furthermore, there is no significant difference in incidence
rates of adverse effects between the two modalities.
Finally, our results show that anemia is prognostic of poor
outcome in patients with OCC.
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